Balyasny Asset Management’s Procept Biorobotics PRCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$19.1M Buy
1,048,790
+1,020,589
+3,619% +$20.3M 0.02% 790
2026
Q2
$637K Sell
28,201
-45,741
-62% -$1.15M ﹤0.01% 2421
2026
Q1
$1.85M Buy
+73,942
New +$2.08M ﹤0.01% 1815
2024
Q1
– Sell
-37,797
Closed -$1.58M – 3011
2023
Q4
$1.58M Buy
37,797
+11,060
+41% +$377K ﹤0.01% 1521
2023
Q3
$877K Buy
+26,737
New +$912K ﹤0.01% 1597
2021
Q4
– Sell
-29,355
Closed -$1.12M – 2524
2021
Q3
$1.12M Buy
+29,355
New +$1.13M ﹤0.01% 1301

Other funds holding PRCT

Balyasny Asset Management's PRCT Position: Q3 2026 in Review

Balyasny Asset Management increased its Procept Biorobotics (PRCT) stake by 3,619% in Q3 2026, buying an estimated $20.3M and bringing the position to 1,048,790 shares worth $19.1M. The position accounts for 0.02% of the portfolio, ranked #790.

Balyasny Asset Management first reported a position in PRCT in Q3 2021 and has held it in 6 quarters since. 232 funds tracked by Wall St. Rank hold PRCT as of Q3 2026.

  • Balyasny Asset Management held 1,048,790 shares of Procept Biorobotics worth $19.1M as of Q3 2026.
  • Balyasny Asset Management bought 1,020,589 Procept Biorobotics shares in Q3 2026, an estimated $20.3M.
  • Procept Biorobotics made up 0.02% of Balyasny Asset Management's portfolio in Q3 2026, its #790 holding.
  • Balyasny Asset Management first reported a position in Procept Biorobotics in Q3 2021 and has held it in 6 quarters since.
  • 232 funds tracked by Wall St. Rank held Procept Biorobotics as of Q3 2026.

Based on Balyasny Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.